Location History:
- Rome, IT (2010 - 2011)
- Pomezia, IT (2011 - 2024)
Company Filing History:
3 out of 47 
2 out of 2,405 
2 out of 28 Years Active: 2010-2024
Title: Immacolata Conte: Innovator in Cyclic Polypeptides
Introduction
Immacolata Conte is a notable inventor based in Rome, Italy. He has made significant contributions to the field of biochemistry, particularly in the development of cyclic polypeptides for the inhibition of PCSK9. With a total of six patents to his name, Conte's work has the potential to impact the treatment of cholesterol-related health issues.
Latest Patents
Conte's latest patents focus on cyclic polypeptide compounds that specifically bind to human proprotein convertase subtilisin/kexin type 9 (PCSK9). These compounds are designed to inhibit the interaction between PCSK9 and the human low-density lipoprotein receptor (LDLR). The pharmaceutical compositions derived from these compounds aim to reduce LDL cholesterol levels in subjects in need of such treatment. This innovative approach could lead to new therapies for managing cholesterol levels effectively.
Career Highlights
Throughout his career, Immacolata Conte has worked with esteemed organizations such as the Istituto di Ricerche di Biologia Molecolare P. Angeletti and Merck Sharp & Dohme Corporation. His experience in these institutions has allowed him to refine his research skills and contribute to groundbreaking advancements in biochemistry.
Collaborations
Conte has collaborated with notable colleagues, including Stefania Colarusso and Frank Narjes. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Immacolata Conte's work in cyclic polypeptides represents a significant advancement in the field of biochemistry. His contributions have the potential to lead to new treatments for cholesterol management, showcasing the importance of innovation in healthcare.